Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
about
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@en
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@nl
type
label
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@en
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@nl
prefLabel
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@en
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@nl
P2093
P2860
P1476
Dasatinib (BMS-35482) interact ...... vation and protein expression.
@en
P2093
Andrew B Nixon
David J Adams
Deanna Teoh
Jingquan Jia
Lisa Grace
Susan K Murphy
P2860
P304
P356
10.1097/IGC.0000000000000056
P577
2014-02-01T00:00:00Z